Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.

@article{Bissada2008OlanzapineIT,
  title={Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.},
  author={Hany Bissada and Giorgio A. Tasca and Ann Marie Barber and Jacques Bradwejn},
  journal={The American journal of psychiatry},
  year={2008},
  volume={165 10},
  pages={
          1281-8
        }
}
OBJECTIVE Anorexia nervosa is associated with high mortality, morbidity, and treatment costs. Olanzapine, an atypical antipsychotic, is known to result in weight gain in other patient populations. The objective of this trial was to assess the efficacy of olanzapine in promoting weight gain and in reducing obsessive symptoms among adult women with anorexia nervosa. METHOD The study was a double-blind, placebo-controlled, 10-week flexible dose trial in which patients with anorexia nervosa (N=34… 
View on PubMed
cckan.ruhosting.nl
200 Citations
Highly Influential Citations
11
Background Citations
48
Methods Citations
6
Results Citations
13

200 Citations

Citation Type

Citation Type

Olanzapine versus placebo for out-patients with anorexia nervosa
TLDR
It is suggested that olanzapine is generally well tolerated by, and may provide more benefit than placebo for out-patients with AN, and further study is indicated to determine whether olanZapine may affect psychological symptoms in addition to BMI.
Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study.
Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial.
  • W. Spettigue, M. Norris, +7 authors A. Buchholz
  • Psychology, Medicine
    Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2018
TLDR
Preliminary results suggest that olanzapine may help facilitate weight gain in adolescents with anorexia nervosa and the importance of medical monitoring over the course of treatment is discussed.
Olanzapine in the treatment of anorexia nervosa: a systematic review
TLDR
Analysis reveals that statistically significant beneficial effect of olanzapine treatment is used at high doses and for short duration, and there is obvious need for more comprehensive further studies, despite the presence of some contradictory studies, olanZAPine treatment has been found beneficial in anorexia nervosa.
A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.
TLDR
Preliminary findings do not support a role for adjunctive olanzapine for underweight adolescent females with anorexia nervosa-restricting type who are receiving standard care in an eating disorder treatment program.
A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.
QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset anorexia nervosa.
  • Blair Ritchie, M. Norris
  • Medicine, Psychology
    Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2009
TLDR
A case of corrected QT (QTc) prolongation associated with atypical antipsychotics use in an adolescent patient with AN is described and safety and medical monitoring issues as it pertains to antipsychotic use in this population are discussed.
Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity.
TLDR
Clinical improvement, in terms of both body mass index (BMI) recovery and global functioning, paralleled the improvement of hyperactivity, and was evident at the end of the first month of treatment, and further increased in the following 5 months, with minimal side effects.
Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials
TLDR
Based on the current evidence, pharmacological treatment of anorexia nervosa with SGAs cannot be generally recommended although some individuals or subgroups of patients might benefit from an antipsychotic medication.
Pharmacotherapy of anorexia nervosa: more questions than answers.
  • J. Hebebrand
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2011
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Olanzapine in the treatment of anorexia nervosa: an open label trial.
TLDR
Findings are promising with clinically significant weight gain in an outpatient setting during a brief 10-week period.
An open trial of olanzapine in anorexia nervosa.
TLDR
The data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa, however, a controlled trial is necessary to demonstrate that oanzapine is efficacious.
Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa.
TLDR
Olanzapine may be of benefit in anorexia nervosa by causing a reduction inAnorexic rumination.
Does fluoxetine augment the inpatient treatment of anorexia nervosa?
TLDR
Fluoxetine does not appear to add significant benefit to the inpatient treatment of anorexia nervosa and there were no significant differences in clinical outcome on any measure between patients receiving fluoxettine and patients receiving placebo.
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
TLDR
Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenic psychopathology, with a substantially more favorable safety profile, than haloperidol and meets several of the criteria for a novel atypical antipsychotic agent.
The Role of Olanzapine in the Treatment of Anorexia Nervosa
TLDR
Although olanzapine appears to have a potential role in the treatment of anorexia nervosa that has been unresponsive to other therapy, randomized, placebo-controlled studies with larger sample sizes are necessary to establish its role in therapy.
Neuroleptics in the Short-Term Treatment of Anorexia Nervosa a Double-blind Placebo-Controlled Study with Sulpiride
Summary There is a remarkable lack of controlled investigations about the usefulness of psychotropic drugs in anorexia nervosa despite the popular use of neuroleptics in these patients. Inspired by a…
No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study.
TLDR
It is concluded that fluoxetine has no robust additive or synergistic therapeutic benefit when measured against the effects of intensive, multidisciplinary inpatient therapy.
Olanzapine therapy in anorexia nervosa: psychobiological effects
TLDR
BMI changes were significant among anorexia nervosa bingeing-purging patient, ‘depression’ (Hamilton Rating Scale) and ‘direct aggressiveness’(Buss–Durkee Rating Scale), among anorxics restricted patients, with a trend toward significance for obsessivity–compulsivity (Yale Brown Cornell for Eating Disorders Rating Scale).
Reports of Olanzapine Treatment of Anorexia Nervosa
TLDR
Two females with severe anorexia nervosa were treated with olanzapine in open trials, associated with weight gain and maintenance as well as reduced agitation and resistance to treatment.
...
1
2
3
4
5
...